97292 ⎘
Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#2CLEC9A BINDING AGENTS
#3BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#4LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
#5CD8 BINDING AGENTS
#6Engineered Heterodimeric Proteins
#7TETRAVALENT MULTISPECIFIC ANTIBODIES
#8BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#9POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#10MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND RELATED METHODS AND USES
#11TETRAVALENT BISPECIFIC AND TETRASPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
#12Antibodies to Amyloid Beta
#13BIFUNCTIONAL FUSION PROTEIN COMPOSED OF IL-15 AND ANTIBODY AGAINST T CELL CO-STIMULATORY MOLECULE
#14T CELL ENGAGER MOLECULES AND USES THEREOF
#15HER2-TARGETING ANTIGEN BINDING MOLECULES COMPRISING 4-1BBL
#16BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#17OPTIMIZED NUCLEIC ACID ANTIBODY CONSTRUCTS
#18BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#19ANTIGEN-BINDING MOLECULE
#20POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#21BISPECIFIC ANTI-HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
#22BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#23MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND METHODS OF USING THE SAME
#24POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#25MULTIVALENT BINDING MOLECULES
#26BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#27MONOCLONAL ANTIBODIES AGAINST BCMA
#28MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND RELATED METHODS AND USES
#29ENGINEERED HETERODIMERIC PROTEINS
#30BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#31LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
#32POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#33PURIFICATION OF MULTISPECIFIC ANTIBODIES
#34Recombinant fusion proteins targeting CD47 and CD24, preparation and use thereof
#35Neutralizing anti-influenza binding molecules and uses thereof
#36MULTISPECIFIC ANTIBODIES
#37BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#38POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#39BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3
#40IgE Antibody with FcRn binding
#41TRUNCATED MULTIVALENT MULTIMERS
#42MULTISPECIFIC ANTIBODIES
#43CLEC9A BINDING AGENTS
#44Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
#45ANTIBODIES BINDING TO GPRC5D
#46BISPECIFIC ANTIBODIES SPECIFIC FOR PD1 AND TIM3
#47BISPECIFIC BINDING CONSTRUCTS WITH SELECTIVELY CLEAVABLE LINKERS
#48ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS
#49T cell activating bispecific antigen binding molecules
#50ANTI-TL1A/ANTI-TNF-ALPHA BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
#51MULTISPECIFIC TREG BINDING MOLECULES
#52CD8 BINDING AGENTS
#53POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#54BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR
#55ENGINEERED OPSONIN FOR PATHOGEN DETECTION AND TREATMENT
#56TETRAVALENT MULTISPECIFIC ANTIBODIES
#57HER2-BINDING TETRAMERIC POLYPEPTIDES
#58MULTISPECIFIC ANTIBODY SCREENING METHOD USING RECOMBINASE MEDIATED CASSETTE EXCHANGE
#59MULTISPECIFIC ANTIBODIES
#60POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#61BISPECIFIC ANTIBODIES
#62Heterodimeric antibodies that bind fibroblast activation protein
#63Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
#64Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies
#65BISPECIFIC SIGNALING AGENTS AND USES THEREOF
#66TRISPECIFIC INHIBITORS FOR CANCER TREATMENT
#67Bispecific HIV-1-neutralizing antibodies
#68Method for increasing the percentage of monomeric antibody Fab-dsFv multimeric species
#69Neutralizing anti-influenza binding molecules and uses thereof
#70BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#71POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#72HER2-targeting antigen binding molecules comprising 4-1BBL
#73Multivalent binding molecules
#74Antagonists targeting the TGF-β pathway
#75IMMUNOTOXIN CONJUGATES FOR USE IN THERAPY
#76Bispecific antigen binding proteins
#77Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
#78Multispecific binding molecules having specificity to dystroglycan and laminin-2
#79Anti-HERV-K envelope protein antibodies and methods for detecting HERV-K envelope protein in patients with sporadic amyotrophic lateral sclerosis
#80Engineered opsonin for pathogen detection and treatment
#81Bispecific HER2 antibodies and methods of use
#82Engineered opsonin for pathogen detection and treatment
#83MONOCLONAL ANTIBODIES AGAINST BCMA
#84Bispecific T cell activating antigen binding molecules
#85Antagonists targeting the TGF-β pathway
#86Heterodimeric antibodies that bind CD3 and PSMA
#87BISPECIFIC ANTI-HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
#88POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#89Humanized antibodies binding to amyloid-beta (A-beta)
#90Heterodimeric antibodies that bind fibroblast activation protein
#91Methods and antibody compositions for tumor treatment
#92Neutralizing anti-influenza binding molecules and uses thereof
#93Engineered opsonin for pathogen detection and treatment
#94Engineered heterodimeric proteins
#95PROTEINS BINDING BCMA, NKG2D AND CD16
#96Bispecific signaling agents and uses thereof
#97TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
#98Monoclonal antibodies against BCMA
#99Clec9A binding agents
#100LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
#101POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#102Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
#103Methods for alleviating symptoms of sporadic amyotrophic lateral sclerosis by neutralizing a HERV-K envelope protein using an anti-HERV-K envelope protein antibody
#104MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND RELATED METHODS AND USES
#105Bispecific antibodies specific for PD1 and TIM3
#106Heterodimeric immunoglobulin constructs and preparation methods thereof
#107BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR
#108BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#109Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
#110CD8 binding agents
#111Antibodies specific for DR5 and methods of use
#112POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#113Bispecific antibody platform
#114T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES
#115Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
#116Bispecific T cell activating antigen binding molecules
#117Bispecific T cell activating antigen binding molecules
#118Blood-brain barrier permeable peptide compositions comprising a VAB domain of an anti-amyloid-beta camelid single-domain heavy-chain only antibody
#119Bispecific antibodies specifically binding to PD1 and LAG3
#120BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#121Nucleic acid encoding dual Fc antigen binding proteins
#122ANTI-CD3XROB04 BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#123BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#124TETRAVALENT BISPECIFIC AND TETRASPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
#125Antibody fragments, compositions and uses thereof
#126Multispecific binding molecules having specificity to dystroglycan and laminin-2
#127Bispecific HIV-1-neutralizing antibodies
#128Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
#129Method for the selection of antibodies against BCMA
#130Bispecific T cell activating antigen binding molecules
#131Bispecific T cell activating antigen binding molecules
#132POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#133Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
#134Neutralizing anti-influenza binding molecules and uses thereof
#135Method for increasing the percentage of monomeric antibody Fab-dsFv multimeric species
#136Bispecific T cell activating antigen binding molecules
#137USE OF CAR-MODIFIED HUMAN NATURAL KILLER CELLS TO TREAT CANCER
#138Engineered opsonin for pathogen detection and treatment
#139Bispecific T cell activating antigen binding molecules
#140Bispecific antigen binding proteins
#141Multispecific antibodies facilitating selective light chain pairing
#142Monovalent antigen binding proteins
#143Domain-exchanged antibody
#144BISPECIFIC MOLECULE BINDING TLR9 AND CD32 AND COMPRISING A T CELL EPITOPE FOR TREATMENT OF ALLERGIES
#145Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
#146BISPECIFIC MOLECULE BINDING TLR9 AND CD32 AND COMPRISING A T CELL EPITOPE FOR TREATMENT OF ALLERGIES
#147BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND ROR1 FOR USE IN THE TREATMENT OF OVARIAN CANCER
#148Bispecific antibodies against CD3ϵ and BCMA
#149Trispecific inhibitors for cancer treatment
#150POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#151BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
#152Bispecific T cell activating antigen binding molecules
#153BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#154TETRAVALENT MULTISPECIFIC ANTIBODIES
#155MULTISPECIFIC ANTIBODIES
#156Bispecific T cell activating antigen binding molecules
#157Bispecific antibodies specific for PD1 and TIM3
#158BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#159BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#160ANTI-NOTCH3 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
#161Separation of bispecific antibodies and bispecific antibody production side products using hydroxyapatite chromatography
#162Fabs-in-tandem immunoglobulin and uses thereof
#163ENGINEERED OPSONIN FOR PATHOGEN DETECTION AND TREATMENT
#164Trimeric antigen binding molecules
#165Fc-free antibodies comprising two fab-fragments and methods of use
#166HUMAN IGG4 FC POLYPEPTIDE VARIANT
#167Bispecific T cell activating antigen binding molecules
#168Antibody fragments, compositions and uses thereof
#169TETRAVALENT BISPECIFIC ANTIBODIES
#170Bispecific antibodies against CD3 and BCMA
#171Method for the selection of antibodies against BCMA
#172Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of use
#173Antibodies with engineered IgG Fc domains
#174BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG2 ANTIBODIES
#175TRI- OR TETRASPECIFIC ANTIBODIES
#176Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5
#177Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
#178Multispecific and multivalent binding proteins and uses thereof
#179Bispecific T cell activating antigen binding molecules
#180Bispecific monoclonal antibody therapeutics against West Nile virus with improved CNS penetration
#181Binding proteins having tethered light chains
#182Protein complexes for antigen binding and methods of use
#183FC-FREE ANTIBODIES COMPRISING TWO FAB FRAGMENTS AND METHODS OF USE
#184Bispecific antigen binding molecules
#185BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE
#186Engineered opsonin for pathogen detection and treatment
#187POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#188Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
#189Monovalent Antigen Binding Proteins
#190Dual FC antigen binding proteins
#191Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodies
#192Tri- or tetraspecific antibodies
#193Bispecific, tetravalent antigen binding proteins
#194Bispecific antigen binding proteins
#195BISPECIFIC MOLECULE BINDING TLR9 AND CD32 AND COMPRISING A T CELL EPITOPE FOR TREATMENT OF ALLERGIES